In the United States, nearly 24,000 people are estimated to receive a brain or nervous system cancer diagnosis in 2020. Even though these cancers represent only about 1 percent of all new cancer cases, brain and other nervous system cancers are the ninth leading cause of cancer-related mortality.
Epithelial ovarian cancer is by far the most common ovarian cancer subtype, accounting for 90 percent of ovarian cancers. The complex genetic heterogeneity of this disease makes treatment particularly difficult. While the introduction of PARP inhibitors to treat ovarian cancers has been a major advancement, only the approximately 50 percent of epithelial ovarian cancers that exhibit defective DNA repair via homologous recombination are potentially responsive to PARP inhibition. Moreover, the development of therapeutic resistance remains a challenge.
Bladder cancer is a common malignancy originating in the bladder, a hollow organ located in the abdomen that stores urine. It is the sixth most prevalent cancer in the United States and has a high rate of recurrence. Over 90 percent of bladder cancers are urothelial carcinomas, which originate in the innermost tissue layer of the bladder lining.
A study finds that the rate of death from opioids was 10 times lower in cancer patients than in the general population between 2006 and 2016
Over the past decade, immune checkpoint inhibitors have transformed cancer care for a variety of tumor types. This form of immunotherapy can lead to long-lasting responses in some patients; however, most patients’ cancers do not respond to this therapy, and those that initially respond may develop resistance.
Researchers present new data on cancer biology, treatment, screening and risk reduction at the AACR Virtual Annual Meeting I.
At the AACR Virtual Annual Meeting I, researchers presented data on blood tests that aim to supplement current cancer screening and speed up diagnosis.
A short time after Mallika Lala, PhD, finished her presentation titled “Pembrolizumab 400 mg Q6W dosing: First clinical outcomes data from Keynote-555 cohort B in metastatic melanoma patients” at the AACR Virtual Annual Meeting I, the U.S. Food and Drug Administration approved the dosing schedule she discussed as a new way to use pembrolizumab (Keytruda) in the treatment of patients with cancer.
Early detection of most cancers is an elusive and daunting task; nevertheless, it has remained a top priority for the cancer research community. Detecting cancer early has manifold advantages: It can increase a patient’s chances of successful treatment, prolong their survival, and substantially improve their quality of life.
Researchers from around the globe share insights into cancer and the coronavirus.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More